Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.38 |
| ▸ | FPR3 | P25089 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23482834 | 0.84 | EPHX2 (0.45) | EPHX2TDP1TSHRMEN1KMT2A | |
| SCHEMBL27437838 | 0.81 | TDP1 (0.62) | EPHX2TDP1MEN1KMT2AGAA | |
| SCHEMBL13329078 | 0.81 | KDM4E (0.50) | EPHX2TDP1TSHRMEN1KMT2A | |
| SCHEMBL22100906 | 0.81 | TDP1 (0.50) | EPHX2TDP1MEN1KMT2AGAA | |
| SCHEMBL30055020 | 0.81 | CA1 (0.44) | EPHX2TDP1TSHRMEN1KMT2A | |
| SCHEMBL2116139 | 0.81 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2EPHX2TDP1MEN1 | |
| SCHEMBL1246619 | 0.81 | TSHR (0.47) | ALDH1A1SMN1; SMN2EPHX2TDP1TSHR | |
| SCHEMBL17746937 | 0.80 | KDM4E (0.49) | EPHX2TDP1TSHRMEN1KMT2A | |
| SCHEMBL31226269 | 0.80 | KDM4E (0.49) | EPHX2TDP1TSHRMEN1KMT2A | |
| SCHEMBL16270971 | 0.80 | TDP1 (0.61) | ALDH1A1SMN1; SMN2TDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452972-B2 | Methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof | XENOPORT, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150197486-A9 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2015-07-16 | — | — | US | disclosed |
| US-20140329818-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | XENOPORT INC (US) | 2014-11-06 | — | — | US | disclosed |
| US-8785443-B2 | Methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof | XENOPORT, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8778991-B2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XENOPORT, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| EP-2650279-A2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XenoPort, Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| US-20120157523-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | XENOPORT, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8148414-B2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XENOPORT, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| EP-2334378-A2 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XenoPort, Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010022177-A2 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157523-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, MGMT, BHMT2 | ALDH1A1 2050/4885SMN1; SMN2 2353/4885EPHX2 608/4885 |
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | FH, MGMT, BHMT2 | ALDH1A1 1970/4885SMN1; SMN2 2337/4885EPHX2 501/4885 |
| US-20150197486-A9 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | FH, MGMT, BHMT2 | ALDH1A1 1970/4885SMN1; SMN2 2337/4885EPHX2 501/4885 |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, MGMT, BHMT2 | ALDH1A1 2050/4885SMN1; SMN2 2353/4885EPHX2 608/4885 |
| US-20140329818-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | FH, MGMT, BHMT2 | ALDH1A1 1970/4885SMN1; SMN2 2337/4885EPHX2 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.